379 related articles for article (PubMed ID: 16648513)
1. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.
Hanrahan EO; Valero V; Gonzalez-Angulo AM; Hortobagyi GN
J Clin Oncol; 2006 May; 24(13):2113-22. PubMed ID: 16648513
[TBL] [Abstract][Full Text] [Related]
2. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
Hanrahan EO; Gonzalez-Angulo AM; Giordano SH; Rouzier R; Broglio KR; Hortobagyi GN; Valero V
J Clin Oncol; 2007 Nov; 25(31):4952-60. PubMed ID: 17971593
[TBL] [Abstract][Full Text] [Related]
3. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome.
Lee AK; Loda M; Mackarem G; Bosari S; DeLellis RA; Heatley GJ; Hughes K
Cancer; 1997 Feb; 79(4):761-71. PubMed ID: 9024714
[TBL] [Abstract][Full Text] [Related]
4. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
Truong PT; Yong CM; Abnousi F; Lee J; Kader HA; Hayashi A; Olivotto IA
J Am Coll Surg; 2005 Jun; 200(6):912-21. PubMed ID: 15922205
[TBL] [Abstract][Full Text] [Related]
5. Pathology and behavior of small breast carcinomas.
Meyer JS; Fahrner M; Daniel FC
Semin Diagn Pathol; 1999 Aug; 16(3):257-68. PubMed ID: 10490202
[TBL] [Abstract][Full Text] [Related]
6. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.
Tan P; Cady B; Wanner M; Worland P; Cukor B; Magi-Galluzzi C; Lavin P; Draetta G; Pagano M; Loda M
Cancer Res; 1997 Apr; 57(7):1259-63. PubMed ID: 9102210
[TBL] [Abstract][Full Text] [Related]
7. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies.
Chia SK; Speers CH; Bryce CJ; Hayes MM; Olivotto IA
J Clin Oncol; 2004 May; 22(9):1630-7. PubMed ID: 15117985
[TBL] [Abstract][Full Text] [Related]
8. Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy.
Dinshaw KA; Budrukkar AN; Chinoy RF; Sarin R; Badwe R; Hawaldar R; Shrivastava SK
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1132-41. PubMed ID: 15978744
[TBL] [Abstract][Full Text] [Related]
9. Safety and feasibility of breast conserving therapy in Indian women: two decades of experience at Tata Memorial Hospital.
Dinshaw KA; Sarin R; Budrukkar AN; Shrivastava SK; Deshpande DD; Chinoy RF; Badwe R; Hawaldar R
J Surg Oncol; 2006 Aug; 94(2):105-13. PubMed ID: 16847919
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant systemic therapy for lymph node-negative breast cancer less than or equal to 1 cm.
Russell CA
Curr Womens Health Rep; 2002 Apr; 2(2):134-9. PubMed ID: 12116603
[TBL] [Abstract][Full Text] [Related]
11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
12. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in node negative premenopausal women treated with breast conserving therapy without adjuvant systemic therapy.
Budrukkar AN; Sarin R; Chinoy RF; Badwe R; Shrivastava SK; Dinshaw KA
Breast; 2008 Jun; 17(3):263-9. PubMed ID: 18060781
[TBL] [Abstract][Full Text] [Related]
14. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
16. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
Di Saverio S; Gutierrez J; Avisar E
Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive factors in early-stage breast cancer.
Cianfrocca M; Goldstein LJ
Oncologist; 2004; 9(6):606-16. PubMed ID: 15561805
[TBL] [Abstract][Full Text] [Related]
19. Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?
Ragage F; Debled M; MacGrogan G; Brouste V; Desrousseaux M; Soubeyran I; de Lara CT; Mauriac L; de Mascarel I
Cancer; 2010 Jul; 116(13):3093-101. PubMed ID: 20564641
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
